Callie Parker’s Post

Automatic, objective, daily remote monitoring powers BIOTRONIK Neuro’s one-of-a-kind proactive care. What does that mean for SCS patients? Join us at #ASPN2024 for “Unparalleled Proactive Care: Clinical Evidence for Prospera™”. At this lunch symposium, we’ll explore the data driving BIOTRONIK Neuro’s spinal cord stimulation (SCS) innovation—the Prospera SCS System with Embrace One™. Register today: https://ow.ly/aGW450SpvBr #BIOTRONIKNeuro

𝗛𝗲𝗮𝗿𝘁 𝗳𝗮𝗶𝗹𝘂𝗿𝗲 𝗰𝗮𝗿𝗲 𝗷𝘂𝘀𝘁 𝗴𝗼𝘁 𝗮 𝗴𝗮𝗺𝗲-𝗰𝗵𝗮𝗻𝗴𝗶𝗻𝗴 𝘂𝗽𝗴𝗿𝗮𝗱𝗲 📢 Today marks a significant milestone as Johnson & Johnson MedTech announces its planned acquisition of V-Wave, a pioneer in heart failure treatment, for $600 million, with potential milestone payments reaching up to $1.1 billion. V-Wave’s Ventura Interatrial Shunt (IAS) is a groundbreaking, minimally invasive solution designed to bring hope to the 800,000 U.S. patients who battle heart failure with reduced ejection fraction (HFrEF) each year. By effectively reducing elevated left atrial pressure, this innovative device addresses a critical need in cardiovascular care. This acquisition not only strengthens J&J’s cardiovascular portfolio but also reaffirms its mission to deliver smarter, less invasive treatments. With an FDA Breakthrough Device Designation and CE mark already secured, the potential for the Ventura IAS to change lives is immense. For those in the medical device industry, this is a testament to the power of innovation and collaboration in addressing some of the most pressing healthcare challenges. Excited to see how V-Wave's cutting-edge technology will flourish as part of the J&J family! #MedTech #HealthcareInnovation #Cardiovascular #HeartFailure #JohnsonAndJohnson #VWAVE #MedicalDevices

More exciting news to share!

Year-End Review Post #4: Speaking at LSI Barcelona 2023 Honored to have been a part of LSI Barcelona 2023 in September 2023! It was exciting to share insights and our newly generated knowledge about single-shot-short-duration heart ablation as a speaker at this esteemed event. Grateful for the opportunity to contribute to the dialogue on Pulmonary Vein Isolation as first line therapy for atrial fibrillation (AFib), the leading cause for stroke. Today less than 5% of global patients suffering from atrial fibrillation are treated with heart ablations, the recommended first line therapy to treat atrial fibrillation. Let´s work together to make this essential treatment available to the 95% in need globally. This is a unique humanitarian and commercial chance and millions of patients and a multi-billion dollar market are ahead of us. Outstanding discussions and networking opportunity to exchange thoughts and connect with industry leaders. #AQUAHeart #LSIEurope23 #Speaker #IndustryInsights #afib #pvi #cardiovascular #venturecapital #medicaldevices #stroke #strokeprevention #heartablation

Computational Life's simulation work on Cardiogenic Shock treatments showcases groundbreaking approaches to healthcare. Our insights into device efficacy illuminate paths to personalized care, proving how technology can transform patient outcomes. A fascinating glimpse into the power of medical simulations. #HealthTech #FutureOfMedicine

🔍 Exploring Retrograde Insertion of IVC Filter: A Crucial Bailout Plan In the realm of vascular interventions, the retrograde insertion of an Inferior Vena Cava (IVC) filter emerges as a strategic bailout plan, offering physicians a valuable tool in critical scenarios. 🚑 🔖 Read more at https://lnkd.in/dAKruxhr. 👥 Have you encountered cases where retrograde IVC filter insertion played a pivotal role? Share your experiences and insights. #VascularIntervention #IVCFilter #MedicalInnovation

Key takeaways: 6 months is not a long time 🥸, however this news is encouraging 😁 🔹 Abbott’s Aveir DR leadless pacemaker, the world’s very first dual-chamber pacing solution of its kind, is associated with a “reliable” performance after six months, according to new data published in Heart Rhythm.[1] 🔷 The Aveir DR system includes both an atrial leadless pacemaker (ALP) and a ventricular leadless pacemaker (VLP). The two devices were designed to communicate with one another as needed, helping patients with abnormal heart rhythms receive the care they need at any given time. 🔹 The U.S. Food and Drug Administration (FDA) approved the new-look device in July 2023, making leadless pacing available to a much wider patient population. While single-chamber leadless pacing has been around for several years, most bradycardia patients require dual-chamber pacing.

Discover the benefits of HeartTec cardiac diagnostics today ❤️

How are new products changing the way we treat glaucoma patients? Please see attached the link to the recording of the interventional glaucoma symposium hosted at the APAO 2024 in Bali earlier this year. Presenter Prof. Shamira Perera (Singapore) explores this question with Prof. Michell Lawlor (Australia), Prof. Tina Wong (Singapore), Dr. Colin Clement (AU), Dr. Leonard Yip (SG), Dr. Robert Ang (PH) and Dr. Bryan Ang (SG) at the APAO 2024 Glaukos Dinner Symposium. The experts dive deep into the proactive approach to interventional glaucoma, focusing on early diagnostics and intervention, along with patient noncompliance with treatment, slow-release medication devices, SLT as the first line of treatment and more. https://lnkd.in/gVPRbm_h Great discussions amongst some of the biggest names in glaucoma in our region.

The #SMARTtrial data makes a difference for women. With its focus on patients with small annuli, 87% of those enrolled in this late-breaking trial were women. Explore how the Evolut™ #TAVR valve design delivers superior outcomes for women with small annuli vs. SAPIEN platform at 1 year:¹ https://bit.ly/49SGIU1 Risk Info: https://bit.ly/3UtKYF2 TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.